Loading
Old version — revision 1
This is a fixed snapshot of Medical microrobots, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/microrobots-in-medicine.md — the filesystem corpus, unchanged. Not an edit.
Micrometre- to millimetre-scale devices steered through the body by external magnetic, acoustic, or biological means, demonstrated in animals and used clinically only as capsule endoscopes.
Medical microrobots are small untethered devices — from a few micrometres to a few millimetres — that are moved through the body by fields applied from outside it and made to deliver a drug, remove material, or take a measurement. They differ from the machines described in Medical nanorobots in two ways that matter: they are larger by three to six orders of magnitude in volume, and they carry no intelligence, since decisions are made by an operator or a control algorithm outside the patient. That makes them a real engineering discipline with working prototypes rather than a design tradition, and it also makes them much less capable than the devices the Molecular assembler literature imagines.
Propulsion at this scale is governed by viscosity. A body a few micrometres across in water has a Reynolds number around 10⁻⁵, meaning inertia contributes nothing and any motion that reverses itself exactly produces no net displacement. Effective swimmers must therefore break time-reversal symmetry, which is why the dominant design is a helix rotated by an external field: a corkscrew turning in a viscous fluid advances, and reversing the rotation reverses the direction.
Magnetic actuation splits into two regimes. Pulling a device with a field gradient produces a force proportional to the device's volume, so it works for millimetre-scale objects and becomes useless as the device shrinks. Rotating a magnetised body in a uniform field produces a torque that scales more favourably, and converting that torque into translation through a chiral shape is the standard approach for micrometre-scale swimmers.
Alternatives exist for cases where magnetism is awkward. Acoustic fields push particles toward nodes of a standing wave or drive oscillating bubbles that generate streaming. Catalytic motors decompose a fuel asymmetrically and are propelled by the products; the classic platinum-and-peroxide design uses a fuel that is toxic at working concentrations, while magnesium and zinc motors react with water or gastric acid and are consumed as they go.
| Dimension | Magnetic | Acoustic | Chemical |
|---|---|---|---|
| Energy source | External field coils | External transducer | Onboard or ambient fuel |
| Effective at depth | Yes, fields penetrate tissue | Attenuates through bone and gas | Yes, but fuel-limited |
| Individual addressing | Difficult; field acts on all | Difficult | Not possible |
| Main drawback | Bulky clinical-scale coils | Poor spatial precision | Fuel toxicity or short life |
The most efficient microswimmers available are the ones evolution already built, and one branch of the field simply attaches cargo to them. Magnetotactic bacteria contain chains of magnetite crystals that align them with magnetic fields and also seek low-oxygen environments; loaded with drug-carrying liposomes and directed by an external field, they penetrated hypoxic regions of tumours in mice more effectively than passive particles.1 Motile algae, sperm cells, and immune cells have all been used as carriers in laboratory and small-animal studies. A separate line of work assembles the swimmer itself out of cells rather than borrowing one that already exists, producing the motile constructs described in Xenobots.
Biohybrids trade control for capability. They swim well, sense chemical gradients, and need no external power, but they replicate, provoke immune responses, and cannot be switched off. Deploying a live engineered organism as a therapeutic device raises the containment questions handled by synthetic auxotrophy and other approaches described in Genetic code expansion and recoding, which are stronger safeguards than anything available for an unmodified strain.
One class of device is in routine clinical use, and it is the largest and simplest. Magnetically steered capsule endoscopes — swallowable cameras roughly a centimetre long, moved by an external magnet under an operator's control — are used in several countries to examine the stomach without sedation, achieving agreement with conventional gastroscopy that is good enough for screening in the reported studies. They are robots by the loose definition used in this field: untethered, actuated, and externally controlled.
Nothing smaller has been approved for therapeutic use anywhere. A related demonstration steered a millimetre-scale ferromagnetic bead through the carotid artery of a living pig using the gradient coils of a standard clinical MRI scanner as both propulsion and imaging system, which showed that existing hospital hardware can in principle serve as the control apparatus.2 The approach has not progressed to human trials.
For comparison, the only untethered implants that routinely operate deep in human tissue are millimetre-scale and stationary: the ultrasonically powered sensors described in Neural dust and ultrasonic implants are read and energised through the same physics microrobots use for propulsion, and they succeed partly because they do not have to move.
Thrombolysis is the most-pursued therapeutic target. Swarms of magnetic microparticles carrying a clot-dissolving enzyme can be concentrated at a thrombus and rotated to increase local mixing, which in animal and flow-model experiments dissolves clots faster and with less systemic enzyme than infusion alone. The appeal is dose reduction: systemic thrombolytics cause bleeding, and confining the drug to the clot would widen a narrow therapeutic window.
The gastrointestinal tract is the friendliest environment, because devices can be swallowed, the lumen is accessible, and anything that fails is eventually excreted. Micromotors powered by gastric acid have been imaged operating in the stomachs of mice, where the propulsion transiently reduced local acidity and improved retention of a payload in the mucosa.
Biofilms are a distinctive application because the task is mechanical rather than pharmacological. Iron oxide microrobot swarms directed by magnetic fields have been used to disrupt and physically remove dental biofilm from extracted teeth and model surfaces, combining catalytic generation of free radicals with sweeping motion that antibiotics cannot reproduce.3
Enclosed fluid compartments — the eye, the bladder, the subarachnoid space — are attractive because the device is not swept away by fast flow and can be retrieved or allowed to degrade in place. The vitreous is the best studied, since it is optically transparent, which solves the imaging problem, and since delivering drugs or cells to the retina is otherwise done by repeated injection, a burden familiar from work on Retinal implants and visual prostheses alternatives. Ingestible origami devices that unfold in the stomach have been proposed for retrieving swallowed button batteries, demonstrated so far only in synthetic models.
Localisation is the binding constraint. Steering requires knowing where the device is, and no imaging modality gives real-time position of a micrometre-scale object several centimetres deep in a human. Ultrasound is fast and safe but resolves poorly at that scale, the same depth-versus-resolution tradeoff that limits focused-ultrasound methods in Non-invasive neuromodulation; photoacoustic imaging is precise and limited to a few centimetres of depth; MRI can localise but is slow, expensive, and difficult to combine with independent magnetic actuation; fluoroscopy delivers ionising radiation. Most published work images devices in transparent phantoms, in small animals, or in tissue thin enough to see through.
Force is the second constraint. Magnetic gradients strong enough to move small devices fall off rapidly with distance from the coils, and generating useful gradients across an adult torso requires equipment on the scale of an MRI magnet.
Then there is what happens to the device afterwards. Anything untethered must be retrieved, excreted, or degraded, and metallic microrobots that lodge in capillaries or in the reticuloendothelial system are a source of long-term toxicity with no precedent in device regulation. Biodegradable materials — magnesium, zinc, gelatin, degradable polymers — address this at the cost of shortening the working life of the device.
Swarm control is unsolved in a specific sense: a global field acts identically on identical devices, so steering thousands of units independently requires deliberately building them differently, and the resulting control problem grows quickly.
The complexity objectionA microrobot carries a very small amount of drug. Delivering a clinically meaningful dose requires either enormous numbers of devices or a payload so potent that leakage would be dangerous. Critics argue that for most indications a well-formulated particle, as covered in Targeted drug delivery, reaches the same tissue at a fraction of the complexity, and that Lipid nanoparticles have already carried nucleic acid cargoes into human cells at industrial scale without moving at all. The counterargument is that microrobots do things formulations cannot: apply mechanical force, move against flow, and be positioned rather than distributed.
The plausible near-term path runs through anatomically accessible compartments and mechanical tasks rather than systemic circulation and drug delivery. Removing obstructions, clearing biofilm from implanted hardware, delivering a payload to a specific point in the gut or the eye — these are jobs where positioning matters, retrieval is possible, and the imaging problem is tractable. Sensing applications may arrive first, since a device that only has to report is easier to build and to justify than one that has to act, and the readouts already exist in Nanoscale diagnostics.
Materials work is converging from a different direction. Structures built by DNA nanotechnology give conditional release with molecular specificity but no mobility; magnetic microrobots give mobility with no specificity. Devices combining an origami payload with a steerable magnetic body have been proposed and not yet shown to work in an animal.
Whether the field converges with the older nanorobot tradition depends on power and sensing, not on mechanics. Untethered devices that can be located precisely and driven at depth would still be operator-controlled instruments rather than autonomous machines, and the step from there to a device that decides what to do inside the body is the same step the designs in Respirocytes and their successors have never been able to specify — a gap wide enough that the runaway scenarios of Grey goo have no purchase on anything this field is building.
paperFelfoul, O. et al. "Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions." Nature Nanotechnology, 2016.↩The carriers are live magnetotactic bacteria injected in tumour-bearing mice, not fabricated devices, and they cannot be switched off.
paperMartel, S. et al. "Automatic navigation of an untethered device in the artery of a living animal using a conventional clinical magnetic resonance imaging system." Applied Physics Letters, 2007.↩A millimetre-scale bead in a living pig; the scanner supplied both propulsion and imaging, and the method never went further than the animal.
paperHwang, G. et al. "Catalytic antimicrobial robots for biofilm eradication." Science Robotics, 2019.↩Biofilm was removed from extracted teeth and model surfaces, not from a patient's mouth.